
Introduction

PROM, cancer
CANCER, DISEASE PROGRESSION
Immune checkpoint inhibitors (ICI) have become part of the standard of treatment for an expanding range of cancer types [These IrAE are notably heterogeneous, occasionally resembling disease progression and mimicking auto-immune conditions [Patient education and symptom self-management, particularly self-monitoring, contribute to more timely detection of IrAE, better short-term outcomes for patients, and lower incidence of chronic symptoms [The use of patient-reported outcome measures (PROM) has been shown to improve symptom detection, monitoring, and management by empowering patients to convey their perception of symptoms to healthcare providers, while also providing valuable treatment safety and tolerability data [Studies involving the use of electronic PRO (ePRO) data in oncology reported a decrease in hospitalization rates and emergency department visits, with favorable outcomes on quality of life, perceived self-efficacy, and overall survival [In this report, we describe the development of a model of care that leverages ePRO data to monitor and manage symptoms in patients treated with ICI, in an outpatient care setting. This model is currently being tested in a randomized controlled phase II trial, the IePRO trial, at two Swiss university hospitals (